Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Priyanka Iyer et al.|Thyroid|2024Cited by 72
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Charles Lu et al.|JAMA Oncology|2024Cited by 35
Low‐dose and long‐term azithromycin significantly decreases <i>Staphylococcus aureus</i> in the microbiome of refractory CRS patientsAxel E. Renteria, Martin Desrosiers, Anastasios Maniakas et al.|International Forum of Allergy & Rhinology|2020Cited by 18
Recent advances in anaplastic thyroid cancer managementSarah Hamidi, Anastasios Maniakas|Current Opinion in Endocrinology Diabetes and Obesity|2023Cited by 13
<i>NTRK</i> Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente Rodrigues Marczyk, Maria E. Cabanillas, Sasan Fazeli et al.|JCO Precision Oncology|2025Cited by 10